Search

Displaying results 2881 - 2890 of 10000 in total
  1. Drug

    Thiopental

    go.drugbank.com/drugs/DB00599
    ApprovedInvestigationalVet approvedWithdrawn

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p920) … It has been used in neurosurgical patients to reduce increased intracranial pressure. It does not produce any excitation but has poor analgesic and muscle relaxant properties.

  2. Drug

    Berahyaluronidase alfa

    go.drugbank.com/drugs/DB22790
    ApprovedInvestigational

    It is used in a fixed-dose combination with [pembrolizumab] for subcutaneous injection. … This combination was approved by the US FDA in September 2025 and is indicated for various solid tumors in adults and pediatric patients 12 years and older, offering a subcutaneous option for indications

  3. Drug

    Carindacillin

    go.drugbank.com/drugs/DB09319
    ApprovedWithdrawn

    Carindacillin or Carbenicillin isdanyl was an oral penicillin prodrug of [carbenicillin] marketed by Pfizer as Geocillin. It is no longer marketed in the United States.

  4. Drug

    Fosphenytoin

    go.drugbank.com/drugs/DB01320
    ApprovedInvestigational

    Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures.

  5. Drug

    Maxy-G34

    go.drugbank.com/drugs/DB05718
    Investigational

    , while Neulasta has a single 20 Kd PEG group attached at the N terminal end of the wild type G-CSF protein. … MAXY-G34 is pegylated with 5 kd mPEG SPA (succinimidyl propionate) groups at 3 amino acid residues, including PEG groups attached at the amino terminal end of the protein and at two internal lysine residues

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Conjugated estrogens

    go.drugbank.com/drugs/DB00286
    ApprovedInvestigational

    [T475] The conjugated estrogen mixture was approved for marketing in US in 1942 based on the efficacy against certain conditions. … Both of these products are later conjugated to natrium sulfate by ester bonds in order to make them more water soluble.

  7. Drug

    Vutrisiran

    go.drugbank.com/drugs/DB16699
    ApprovedInvestigational

    [A249010] Vutrisiran was approved by the FDA in June 2022. … [A249010] TTR mutations lead to the formation of misfolded TTR proteins, which form amyloid fibrils that deposit in different types of tissues.

  8. Drug

    Andexanet alfa

    go.drugbank.com/drugs/DB14562
    Approved

    It was developed by Portola Pharmaceuticals and was approved in in May 2018. … Rivaroxaban and apixaban are Factor Xa inhibitors that promote anticoagulation in situations where blood clotting is unfavourable, such as in deep vein thrombosis and pulmonary embolism.

  9. Drug

    Aflibercept

    go.drugbank.com/drugs/DB08885
    ApprovedInvestigational

    [L47976] An aflibercept biosimilar, Yesafili, was approved for use in the EU in September 2023. … [L47915] All five putative N-glycosylation sites on each polypeptide chain predicted by the primary sequence can be occupied with carbohydrates and exhibit some degree of chain heterogeneity, including

    Products: EYLEA SOLUTION FOR INJECTION IN VIAL 2MG, EYLEA 40MG/ML SOLUTION FOR INJECTION IN VIAL
  10. Drug

    Centanafadine

    go.drugbank.com/drugs/DB14841
    ApprovedInvestigational

    [L63806] Its mechanism in ADHD is unclear, but its efficacy may be mediated by this triple reuptake inhibition, which increases the availability of all three neurotransmitters in pathways involved in attention … reuptake inhibitor, positioning it as a new mechanistic option in a condition where response varies widely between individuals and many patients remain symptomatic on existing treatment.